CDMO acquires Meppel facility from Astellas
European Pharmaceutical Review
APRIL 9, 2024
Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas. The 31,600 square meter facility produces some 40 million finished solid dosage forms each year, including tablets, capsules and pellets. The company employs more than 6,500 people, generating revenues of €1.1
Let's personalize your content